Population PK modelling as an alternative route to bioequivalence

Abstract

Demonstrating bioequivalence (BE) is important for the development of lower-cost generic products, and also for approving post-submission manufacturing changes. However, for many complex parenteral products, BE demonstration can be very challenging. For example, long-acting injectable products are engineered to have an extended release over several weeks or months, but this also means that traditional BE study can take many months or years to perform. Here, we summarise how population PK modeling, which captures differences in PK profiles due to population variation, could be used to explore hundreds of virtual formulations, and thus determine a range of products that are bioequivalent after both multiple and single dosing. This provides a guide for formulation development but also opens alternative, more streamlined routes to BE assessment. 

Keywords

Bioequivalence, Population PK Modelling, Complex Parenterals, Long acting injectables

How to Cite

Gajjar, P., Dickinson, J., Dickinson, H., Ruston, L., Mistry, H. B., Patterson, C. & Dickinson, P. A., (2022) “Population PK modelling as an alternative route to bioequivalence”, British Journal of Pharmacy 7(2). doi: https://doi.org/10.5920/bjpharm.1186

535

Views

109

Downloads

Share

Authors

Parmesh Gajjar (Seda Pharmaceutical Development Services)
Jake Dickinson (Seda Pharmaceutical Development Services)
Harri Dickinson (Seda Pharmaceutical Development Services)
Linette Ruston (Seda Pharmaceutical Development Services)
Hitesh B Mistry (Seda Pharmaceutical Development Services)
Claire Patterson (Seda Pharmaceutical Development Services)
Paul A Dickinson (Seda Pharmaceutical Development Services)

Download

Issue

Dates

Licence

Creative Commons Attribution 4.0

Identifiers

Peer Review

This article has been peer reviewed.

File Checksums (MD5)

  • Full text: adb84467c4c759b229a38783b9b601b5